Teva (TEVA) director converts 14,492 restricted units into ordinary shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries director Ronit Satchi-Fainaro exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units converted into 14,492 ordinary shares at a stated exercise price of $0.00 per unit, reflecting RSU vesting rather than an open-market purchase.

These RSUs were originally granted on June 5, 2025 and vested on June 5, 2026. After the settlement, Satchi-Fainaro directly holds 112,401 ordinary shares. The filing shows an acquisition of shares through equity compensation, with no reported open-market buying or selling.

Insider Trade Summary

14,492 shares exercised/converted

Mixed 2 txns

Insider Satchi-Fainaro Ronit

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	14,492	$0.00	--
Exercise	Ordinary Shares	14,492	$0.00	--

Holdings After Transaction: Restricted Share Units — 0 shares (Direct, null); Ordinary Shares — 112,401 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Key Figures

RSUs exercised: 14,492 units Shares acquired: 14,492 ordinary shares Exercise price: $0.00 per unit +4 more

7 metrics

RSUs exercised 14,492 units Restricted share units converted on June 5, 2026

Shares acquired 14,492 ordinary shares Delivered upon RSU vesting and settlement

Exercise price $0.00 per unit Stated conversion price for restricted share units

Holdings after transaction 112,401 shares Ordinary shares directly held post-transaction

RSU grant date June 5, 2025 Grant date of restricted share units that vested

RSU vesting date June 5, 2026 Vesting date triggering share delivery

ADS ratio 1 ADS : 1 ordinary share Each ADS currently represents one ordinary share

Key Terms

Restricted Share Units, American Depositary Shares, contingent right, derivative exercise/conversion, +1 more

5 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or the cash value."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

contingent right financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or the cash value."

derivative exercise/conversion financial

"transaction_action is described as derivative exercise/conversion for the RSU transaction."

ordinary share financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share."

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Satchi-Fainaro Ronit

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/05/2026		M		14,492	A	(2)	112,401	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	06/05/2026		M			14,492	(3)	(3)	Ordinary Shares(1)	14,492	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

	/s/ Dov Bergwerk as attorney-in-fact for Ronit Satchi-Fainaro	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Teva (TEVA) director Ronit Satchi-Fainaro report?

Ronit Satchi-Fainaro reported exercising restricted share units into ordinary shares. On June 5, 2026, 14,492 RSUs converted into 14,492 Teva ordinary shares as part of an equity compensation arrangement, not an open-market stock purchase or sale.

How many Teva shares did Ronit Satchi-Fainaro acquire in this Form 4 filing?

The director acquired 14,492 Teva ordinary shares. These came from the vesting and settlement of 14,492 restricted share units, each delivering one ordinary share or equivalent cash value, rather than from buying shares on the open market.

What are the terms of the restricted share units reported for Teva (TEVA)?

Each restricted share unit represents a contingent right to receive one ordinary share or its cash value. The RSUs involved in this filing were granted on June 5, 2025 and vested on June 5, 2026, triggering delivery of 14,492 ordinary shares.

Did the Teva (TEVA) director sell any shares in this Form 4 transaction?

No, the Form 4 does not report any sales. It shows an exercise or conversion of 14,492 restricted share units into 14,492 ordinary shares, increasing the director’s direct holdings, with no corresponding open-market disposition reported in this filing.

What is Ronit Satchi-Fainaro’s Teva shareholding after the reported transaction?

Following the RSU conversion, Ronit Satchi-Fainaro directly holds 112,401 Teva ordinary shares. This figure reflects her position after receiving 14,492 shares from vested restricted share units as disclosed in the Form 4 insider transaction report.

How are Teva ordinary shares related to American Depositary Shares (ADS)?

Teva’s ordinary shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one ordinary share, providing a way for investors to hold Teva equity through ADSs while referencing the underlying ordinary shares.